Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Royalty Pharma Plc Cl A (NQ: RPRX ) 28.47 +0.33 (+1.17%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,226,645 Open 28.27 Bid (Size) 27.93 (1) Ask (Size) 28.58 (2) Prev. Close 28.14 Today's Range 28.04 - 28.50 52wk Range 25.20 - 31.66 Shares Outstanding 388,132,400 Dividend Yield 2.81% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 July 19, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Declares Third Quarter 2024 Dividend July 17, 2024 From Royalty Pharma plc Via GlobeNewswire Performance YTD +0.71% +0.71% 1 Month +5.80% +5.80% 3 Month +2.34% +2.34% 6 Month -2.63% -2.63% 1 Year -8.16% -8.16% More News Read More Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? July 11, 2024 Via Investor's Business Daily Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 June 26, 2024 Via InvestorPlace 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 Via InvestorPlace NASDAQ:RPRX: good value for what you're paying. April 24, 2024 Via Chartmill Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields June 12, 2024 Via Benzinga June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge June 05, 2024 Via InvestorPlace Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes June 03, 2024 From Royalty Pharma plc Via GlobeNewswire Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? May 28, 2024 Via Benzinga Exposures Product Safety Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out May 28, 2024 Via Investor's Business Daily Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million May 28, 2024 From Royalty Pharma plc Via GlobeNewswire Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe May 23, 2024 Via Benzinga Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline May 22, 2024 From Royalty Pharma plc; Cytokinetics Via GlobeNewswire 7 Dividend Stocks to Buy at a 52-Week Low May 20, 2024 Via InvestorPlace Royalty Pharma to Present at Upcoming Investor Conferences May 13, 2024 From Royalty Pharma plc Via GlobeNewswire RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Royalty Pharma Reports First Quarter 2024 Results May 09, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab May 09, 2024 From Royalty Pharma plc Via GlobeNewswire Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment May 02, 2024 Via Benzinga Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 April 19, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Declares Second Quarter 2024 Dividend April 17, 2024 From Royalty Pharma plc Via GlobeNewswire 3 Pharma Stocks to Sell in April Before They Crash & Burn April 11, 2024 Via InvestorPlace Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of) April 09, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.